CDVAX is a project funded under the European Union 7th Framework Programme. The aim of CDVAX is to take forward a novel and highly innovative oral vaccine that will provide protection against Clostridium difficile infection. This novel approach will use the spores of a genetically engineered harmless bacteria to generate a vaccine to protect vulnerable patients against this serious and life threatening hospital acquired infection. This project will develop the vaccine and evaluate it in a human clinical trial.

To learn more about Clostridium difficile and the illness it causes click here.

Project title

Oral Vaccination against Clostridium difficile Infection.

Work Programme

“Drugs and vaccines for infections that have developed or are at risk of developing significant anti-microbial resistance”.

Project Coordinator

Professor Simon Cutting
School of Biological Sciences,
Royal Holloway University of London, UK
E-mail: s.cutting@rhul.ac.uk
Phone: +44-(0)1784 443760
Fax: +44 (0)1784 414224


The project is being implemented by a consortium of five partners, four of whom are Small-Medium Enterprises (SMEs). Further details can be found here. The consortium is supported by a Scientific Advisory Board.